The Princess Margaret Cancer Foundation

The Princess Margaret Cancer Foundation

The Princess Margaret Cancer Foundation was established in 1982. Dr. Miyo Yamashita serves as president and chief executive. The organization operates without a disclosed family wealth origin and instead aggregates donations from individuals and institutions. The foundation allocates 10.33 percent of assets to private equity. It maintains positions in Adela and Treadwell Therapeutics through its Accelerator Fund. Geographic exposure centers on Canada with secondary activity in the United States. Capital also supports direct ownership of commercial buildings including 522 University Avenue and the Princess Margaret Cancer Research Tower. The foundation employs an Investment Committee to oversee asset allocation and applies a tobacco exclusion policy. It lists Ernst & Young as auditor and retains Starlight Capital, Burgundy Asset Management, and Brookfield Asset Management as investment advisors. Additional offices are not disclosed. Recent operational activity centers on annual fundraising events such as the Ride to Conquer Cancer. The foundation maintains a distinct governance structure through its formal relationship with University Health Network, which separates philanthropic fundraising from hospital operations while directing all net proceeds to the cancer centre.